CBX5 and cancer: In the study conducted by Zhao and colleagues on nasopharyngeal carcinoma, targeting HP1ß inhibited STAT1 activation via IFNγ, which led to lowered PD-L1 expression and, as such, enhanced cancer cell killing by CAR T-cells [132].